Please subscribe to us, we are worth your time and will keep you informed!
RECAP OF LAST WEEK AND RESULTS:
Square: We called for it to go past $245 this week and it went to $272.97.
We alerted our premium subscribers for a call option this Monday. It would have returned over 100%
Walmart: We called for it to move to $151.40 from $144, we got the right direction but slightly overshot its price, expecting upward movement from it this weekend.
Aurinia Pharmaceuticals: We called it to move to $17 from $15.75. It stayed flat this week, the price is waiting for news of buyout or prescription numbers to be released. They moved their earnings up one week early. Could be a sign of positive news ahead.
IN THIS ISSUE
Earnings run-up expected, growth in their space is expected as well. Pinterest correlates.
Recreational Marijuana legalized? Retail Investors start moving markets to other places.
FDA approval of breast cancer drug anytime from now until February 28th.
Etsy is an online marketplace where artists, inventors, entrepreneurs can sell their handcrafted goods. Etsy takes a small percentage of each component of the sale. They make money when someone lists an item and then take a percentage on the transaction. Many people are starting to use this service in the pandemic. It seems that there is no slowing right now as many have become independent of an employer and are making a living by making goods and selling them on Etsy.
Current Price: $232
One Week Target: $240
One Month Target: $265-280
One Year Target: $200
The stock price is in an uptrend and we expect it to keep running to around $240 before earnings. One interesting correlating business that just had their earnings is Pinterest. This company did extremely well and crushed their earnings. We think Etsy and Pinterest have similar business models so we are using that as our edge going into earnings. We think Etsy has more of an edge because Pinterest relies on using targeted advertising, while Etsy has targeted advertising and alternate methods to create cash for the business.
Long term, we think this price will come down from Etsy’s highs and sit near $200, the market is stretched and we think it will return down by mid-year 2021.
This is a buy-in our opinion before earnings. We look to sell before earnings to reduce our risk.
Tilray : TLRY
“Tilray is a global leader in cannabis research, cultivation, processing, and distribution.” Tilray has been on the stock market since July 19, 2018, and it reached a high of $148. However, that did not last as the stock price dropped back down to $4 a share over a few months. Now Tilray and other cannabis stocks were in the spotlight this past week as Reddit decided its next move would be to the cannabis sector. The stock price increased 102.50% in the last month and reached a high of $63.80 before moving back down and finishing at $29.30
Current Price: $29.66
One Week Target: $23-24
One Month Target: $30
One Year Target: $50
The reason we are writing about this stock is the potential for these companies to grow. “The day traders behind GameStop Corp.’s meteoric rise last month are turning their attention to cannabis stocks, betting that President Biden’s administration will push for further decriminalizing the drug.” We think there is a good chance of getting cannabis legalized at the federal level which would cause these stocks like Tilray to go up. But just like any company, you have good ones and bad ones. We think Tilray could be a huge winner down the road.
Tilray will report their 4th quarter earnings on February 17th after hours which should give us a better look at the company. They also got a deal for medical usage in the U.K. Keep an eye on the stock this week to see if it pulls back more. We are looking to buy into some positions and plan to hold them for 5 years. Upside potential is high (pun intended) in the cannabis sector and if the United States does legalize a large price jump may be seen in the stock value when that occurs.
“Total revenue of $51.4 million ( C$68.1 million ) was flat compared to the third quarter of 2019. Cannabis segment revenue decreased 11% to $31.4 million” However Tilray and Aphria have agreed to merge in 2021 and stay under the ticker TLRY. Aphria has been showing more and more promise as numbers are increasing.
This stock is a buy-in our opinion.
Athenex is a company that is looking to cure cancers. They have a moderately wide pipeline of drugs being researched at the moment for cancers. One of their drugs has already been approved. It is a topical skin cancer cream.
The big news surrounding Athenex is that they have a drug looking to treat metastatic breast cancer. If approved by the FDA on or before February 28th, patients will have access to an oral medication rather than using IVs to treat their breast cancer. This could increase the share price of the company to over 20+ assuming that the drug could bring in revenues of over 1 billion a year. The company has 100 Million in cash, and are currently making revenue each year off of their topical skin cancer treatment drug.
Current Price: $13.10
One Week Target: $15
One Month Target: $20
One Year Target: $30
PDUFA for Oral Paclitaxel which treats Metastatic Breast Cancer targeted Feb 28th
FDA gave positive feedback for Phase 3 trial design
Phase 3 showed superior results for Oral Paclitaxel compared to IV Paclitaxel
Treatment could allow in-home treatment vs. Hospital-based treatments - good for the COVID environment
Over 100M in cash and other nondilutive arrangements
Will receive a 50M milestone payment upon FDA approval
Has a team of Medical Science Liaisons and others ready to launch commercialization
Perceptive, Blackrock, and other large institutional investors
Source: clankclank - Stocktwits
We are buying this now as it has dropped to a low price from its 52-week highs. Expecting a large increase in share price if the drug is approved. To around $21-26 a share. We are parking some shares in this one as we believe they will receive approval.
Thanks for joining us. If you find this information helps you, please share it with someone else! It will help us out greatly.
Until next week,
and the Optifinancial Team
Optifinancial is not a certified financial planner/advisor nor a certified financial analyst nor an economist nor a CPA ;nor an accountant nor a lawyer. Optifinancial is not a finance professional through formal education. Optifinancial believes in and takes pride in a sense of freedom, satisfaction, fulfillment and empowerment of money. The contents on this site/letter/email are for informational and entertainment purposes only and does not constitute financial, accounting, or legal advice. Optifinancial can’t promise that the information shared on our posts is appropriate for you or anyone else. By using our content, you agree to hold Optfinancial or any constituents related to Optifinancial harmless from any ramifications, financial or otherwise, that occur to you as a result of acting on information provided through our site, website, social media and newsletter.
Optifinancial does not collect information about you other than (1) what you personally provide if you submit a comment (your email will not be published) or sign up for our newsletter updates and (2) what’s available through normal server logs and Google Analytics. Optifinancial won’t sell or disclose your information to others unless we have received prior written agreement from you (e.g., you agreed to let me share your comment on a post with other readers).
17350 State Highway 249
Ste 220 #3942
Houston, Texas 77064